{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Adiponectin", "Flavones", "NIDDM model", "PPAR\u03b1", "Tilianin"]], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "27470567", "DateCompleted": {"Year": "2017", "Month": "02", "Day": "07"}, "DateRevised": {"Year": "2017", "Month": "08", "Day": "09"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "07", "Day": "26"}], "ELocationID": ["10.1016/j.biopha.2016.07.023", "S0753-3322(16)30217-7"], "Language": ["eng"], "Journal": {"ISSN": "1950-6007", "JournalIssue": {"Volume": "83", "PubDate": {"Year": "2016", "Month": "Oct"}}, "Title": "Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie", "ISOAbbreviation": "Biomed Pharmacother"}, "ArticleTitle": "Antidiabetic, antihyperlipidemic and anti-inflammatory effects of tilianin in streptozotocin-nicotinamide diabetic rats.", "Pagination": {"StartPage": "667", "EndPage": "675", "MedlinePgn": "667-675"}, "Abstract": {"AbstractText": ["Flavonoids from medicinal plants have been used in traditional medicine to treat a variety of prevalent diseases. Flavones activate the signaling pathways promoting fuel metabolism and insulin sensitizing in hepatocytes and adipocytes, which suggests that flavones may have the potential to exert in vivo antidiabetic and antihyperlipidemic effects. Thus, the aim of the current study was to determine the antidiabetic, antihyperlipidemic and anti-inflammatory effects of tilianin in diabetic rats. Also, to understand the mechanism involved using in vitro 3T3-L1 cells and tissues from experimental animals treated with test samples through molecular profile studies. Non insulin-dependent diabetic mellitus (NIDDM) rats were treated over a short period (for 10 days) with 60mg/Kg/day of tilianin. After treatment, a biochemical blood profile was determined. Also, adipose and thoracic aortic tissues were used to determine pro-inflammatory profile, adiponectin and adhesion molecules by real-time PCR. In 3T3-L1 cells pretreated with tilianin (10\u03bcM), PPAR\u03b1, PPAR\u03b3, GLUT4, FATP-1 and ACSL-1 mRNA expression were measured. In order to explain the potential PPAR\u03b1 interaction with tilianin, a docking study with PPAR\u03b1 was carried out. Thus, intragastric administration of tilianin and metformin induced a decrease in plasma glucose (GLU) in diabetic rats on day 6, and remained significantly lower until the end of the treatment; also blood triacylglycerides (TAG) and cholesterol (CHOL) (p<0.05) were diminished. Moreover, IL-1\u03b2 and IL-18 expression was significantly decreased in adipose tissue (p<0.05); meanwhile adiponectin was significantly overexpressed (p<0.05). Besides, ICAM-1 expression was significantly reduced in aortic tissue (p<0.05). In 3T3-L1 cells it was found that tilianin increased PPAR\u03b1 and ACSL1 mRNA levels (p<0.05). Finally, tilianin docking studies with PPAR\u03b1 showed polar interactions with Glu269, Tyr314, His 440 and Tyr464 residues. In conclusion, short-term tilianin treatment might exert its antidiabetic and antihyperlipidemic effect by modulating a pro-inflammatory profile, and increasing adiponectin expression. In addition, our results suggest the possible interaction of tilianin with PPAR\u03b1."], "CopyrightInformation": "Copyright \u00a9 2016 Elsevier Masson SAS. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Facultad de Farmacia, Universidad Aut\u00f3noma del Estado de Morelos, Av. Universidad 1001 Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico."}], "LastName": "Garc\u00eda-D\u00edaz", "ForeName": "Jorge Alberto", "Initials": "JA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Facultad de Farmacia, Universidad Aut\u00f3noma del Estado de Morelos, Av. Universidad 1001 Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico."}], "LastName": "Navarrete-V\u00e1zquez", "ForeName": "Gabriel", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Facultad de Farmacia, Universidad Aut\u00f3noma del Estado de Morelos, Av. Universidad 1001 Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico."}], "LastName": "Garc\u00eda-Jim\u00e9nez", "ForeName": "Sara", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratorio de Farmacolog\u00eda, Depto. Ciencias de la Salud, D.C.B.S., Universidad Aut\u00f3noma Metropolitana-Iztapalapa, Apdo-Postal 55-535, CP 09340, Ciudad de M\u00e9xico, Mexico."}], "LastName": "Hidalgo-Figueroa", "ForeName": "Sergio", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratorio de Farmacolog\u00eda, Depto. Ciencias de la Salud, D.C.B.S., Universidad Aut\u00f3noma Metropolitana-Iztapalapa, Apdo-Postal 55-535, CP 09340, Ciudad de M\u00e9xico, Mexico."}], "LastName": "Almanza-P\u00e9rez", "ForeName": "Julio C", "Initials": "JC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratorio de Farmacolog\u00eda, Depto. Ciencias de la Salud, D.C.B.S., Universidad Aut\u00f3noma Metropolitana-Iztapalapa, Apdo-Postal 55-535, CP 09340, Ciudad de M\u00e9xico, Mexico."}], "LastName": "Alarc\u00f3n-Aguilar", "ForeName": "Francisco Javier", "Initials": "FJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "U.I.M. en Bioqu\u00edmica, Hospital de Especialidades, CMNSXXI, IMSS, Ciudad de M\u00e9xico, Mexico."}], "LastName": "G\u00f3mez-Zamudio", "ForeName": "Jaime", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "U.I.M. en Bioqu\u00edmica, Hospital de Especialidades, CMNSXXI, IMSS, Ciudad de M\u00e9xico, Mexico."}], "LastName": "Cruz", "ForeName": "Miguel", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Tlalnepantla, Estado de M\u00e9xico 54090, Mexico. Electronic address: maxibarrab@hotmail.com."}], "LastName": "Ibarra-Barajas", "ForeName": "Maximiliano", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Facultad de Farmacia, Universidad Aut\u00f3noma del Estado de Morelos, Av. Universidad 1001 Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico. Electronic address: enoch@uaem.mx."}], "LastName": "Estrada-Soto", "ForeName": "Samuel", "Initials": "S"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "France", "MedlineTA": "Biomed Pharmacother", "NlmUniqueID": "8213295", "ISSNLinking": "0753-3322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Blood Glucose"}, {"RegistryNumber": "0", "NameOfSubstance": "Fatty Acids"}, {"RegistryNumber": "0", "NameOfSubstance": "Flavonoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Glycosides"}, {"RegistryNumber": "0", "NameOfSubstance": "Hypoglycemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Hypolipidemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "tilianin"}, {"RegistryNumber": "25X51I8RD4", "NameOfSubstance": "Niacinamide"}, {"RegistryNumber": "5W494URQ81", "NameOfSubstance": "Streptozocin"}, {"RegistryNumber": "9100L32L2N", "NameOfSubstance": "Metformin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "3T3-L1 Cells"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Adipose Tissue"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Aorta"}, {"QualifierName": ["metabolism"], "DescriptorName": "Blood Glucose"}, {"QualifierName": ["blood", "drug therapy", "genetics"], "DescriptorName": "Diabetes Mellitus, Experimental"}, {"QualifierName": ["metabolism"], "DescriptorName": "Fatty Acids"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Flavonoids"}, {"QualifierName": [], "DescriptorName": "Gene Expression Profiling"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression Regulation"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Glycosides"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Hypoglycemic Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Hypolipidemic Agents"}, {"QualifierName": ["drug effects", "genetics"], "DescriptorName": "Lipogenesis"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Metformin"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Niacinamide"}, {"QualifierName": ["drug effects"], "DescriptorName": "Oxidation-Reduction"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": [], "DescriptorName": "Streptozocin"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2016", "Month": "2", "Day": "22"}, {"Year": "2016", "Month": "7", "Day": "12"}, {"Year": "2016", "Month": "7", "Day": "14"}, {"Year": "2016", "Month": "10", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "2", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "7", "Day": "30", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["27470567", "10.1016/j.biopha.2016.07.023", "S0753-3322(16)30217-7"]}}], "PubmedBookArticle": []}